INKmune is under clinical development by Inmune Bio and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INKmune’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INKmune overview
INKmune is under development for the treatment of multiple myeloma, myelodysplastic syndrome, nasopharyngeal cancer and epithelial cancers including breast, metastatic ovarian, prostate, renal and lung cancer. It is also under development for metastatic castration-resistant prostate cancer (mCRPC). It is administered by the intravenous and intraperitoneal routes. It is a biologic delivery system that delivers the missing S1 (priming signal) to the patient’s resting NK cells.
It was also under development for acute myelocytic leukemia, lymphoma, chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome.
Inmune Bio overview
Inmune Bio is a clinical-stage biotechnology company. It develops novel immunotherapies to treat the cancer. The company’s product portfolio includes INKmune, a biologic delivery system that allows delivery of essential priming signals to patients’ resting NK cells; INB03 is a protein biologic inhibitor, for the treatment of cancer, XPro1595, a protein biologic that targets soluble TNF (sTNF) in Alzheimer’s disease. It serves in the therapeutic areas of tumor cells and immune system. Inmune Bio is headquartered in La Jolla, California, the US.
For a complete picture of INKmune’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
